European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases
Financed by : European Commission
Program : EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY (COST) 2021
Duration: November 2022 to November 2026
Although treatment of chronic inflammatory diseases has been revolutionised with the introduction of targeted therapies with therapeutic antibodies, a large portion of patients do not respond to treatment or they lose response over time. This is mainly attributed to suboptimal dosing, immunogenicity and interpatient variability in pharmacokinetics. To overcome the problems of suboptimal treatment, researchers have started to focus on individualised treatment optimisation strategies based on development of patient stratification tools and therapeutic drug monitoring (TDM)-guided dose adaptations based on serum drug concentrations.
A substantial improvement in patient care will be realised by implementing individualised (TDM-guided) dosing schemes of therapeutic antibodies in daily clinical practice for treatment of chronic inflammatory diseases, which will ultimately result in a more cost-effective use of these expensive drugs (“the right drug at the right dose for the right patient”). However, expertise on individualised (TDM-guided) treatment optimisation is highly fragmented in Europe, and largely limited to a few pioneering centres. Transferring knowledge and techniques to other (peripheral) centres is challenging, especially due to the need for inhouse expertise and a lack of standardisation in TDM assays. Therefore, this Action will create an interdisciplinary, pan-European Network in order to defragment and structure the scientific research in this field and to facilitate the implementation of individualised (TDM-guided) cost-effective dose optimisation of therapeutic antibodies in daily clinical practice for treatment of chronic inflammatory diseases.